BANK VONTOBEL/CALL/ELI LILLY & CO/370/0.1/21.06.24 | Delayed Deutsche Boerse AG 14:03:38 2024-05-31 EDT | ||
| 41.08 EUR | -1.49% |
|
| 1 month | +5.96% | ||
| 3 months | +14.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 41.08 | -1.49% |
| 24-05-30 | 41.7 | +1.48% |
| 24-05-29 | 41.09 | +2.85% |
| 24-05-28 | 39.95 | -2.56% |
| 24-05-27 | 41 | +0.61% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 02:03 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6BRZ |
| ISIN | DE000VU6BRZ4 |
| Date issued | 2023-04-17 |
| Strike | 370 $ |
| Maturity | 2024-06-21 (19 Days) |
| Parity | 10 : 1 |
| Emission price | 5.37 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 41.75 € |
|---|---|
| Lowest since issue | 5.2 € |
| Spread | 0.02 € |
| Spread % | 0.05% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Warrants
- Warrant
